

Data Sharing Statement

Hutton. Cost-effectiveness of Aflibercept Monotherapy vs Bevacizumab First Followed by Aflibercept If Needed for Diabetic Macular Edema. *JAMA Ophthalmol.* Published February 02, 2023. doi:10.1001/jamaophthalmol.2022.6142

Data

Data available: Yes

Data types: Deidentified participant data

How to access data: www.drcr.net one year after publication

When available: beginning date: 01-24-2024

Supporting Documents

Document types: None

Additional Information

Who can access the data: anyone

Types of analyses: any

Mechanisms of data availability: without support

Any additional restrictions: none